WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

The popular weight-loss drugs known as GLP-1 receptor agonists, which were originally meant to treat diabetes, surged in ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

However, Clinic Secret has emerged as a potential game-changer in weight loss by offering a clinically proven, accessible solution that leverages the power of GLP-1 medications. In this ...

Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied by the ...

Led by an interest in GLP-1 weight loss drugs, more health care brands may advertise in the Super Bowl this year.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

WVU medicine is conducting a trial to combat weight gain after patients stop taking GLP-1 drugs such as Ozempic. Officials ...